Deals
Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.
The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.
Biocon Biologics has announced the latest milestone in its integration of former partner Viatris’s biosimilars business, completing the move in the US and Canada “ahead of schedule.”
Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.
Hikma CEO Siggi Olafsson has outlined the potential future opportunity that the firm sees in the US biosimilars market, in the second part of an exclusive interview with Generics Bulletin.
Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.
Neuraxpharm will gain a platform in Ireland after striking a deal to acquire local distribution specialist Medinutrix.
Accord Healthcare has struck a European licensing deal with Orexo for its Zubsolv opioid-dependence treatment, building on a CNS business that also includes a recent distribution agreement with Molteni Farmaceutici for Sixmo.
Nidda Healthcare, the investment vehicle controlled by Bain Capital and Cinven, has secured a “timely” squeeze-out of minority shareholders in Stada through settlement terms that include a one-time payment of €0.10 per outstanding share for the remaining shareholders.
Antibiotics specialist Centrient has struck a deal to acquire India’s Astral SteriTech in a move that will expand its portfolio to include sterile injectable finished-dose products.
Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.
The Citeline News & Insights Awards 2025 are now open for entries, inviting organizations, teams, and individuals from across the global life sciences sector to showcase their achievements and innovations. This year’s awards promise to be bigger and more inclusive than ever.
Facing a todo list top-heavy with critical, complex tasks, adults with ADHD often tackle the easier items — ones that keep them busy but not productive. Called “procrastivity,” this self-defeating ADHD time-management habit can be helped by CBT approaches that teach patients how to prioritize tasks.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
Polpharma has struck a deal with MSN Laboratories that will see the Polish generics player distribute the Indian firm’s hospital portfolio in Poland.